TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03352050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mushroom
Study: NCT03150485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
Study: NCT00017316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study: NCT03150485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
Study: NCT03319667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)

Intervention type: DRUG
Group type: OTHER
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous
Study: NCT04024878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
Study: NCT00017316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT03468283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application for diabetes
Description: Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
Study: NCT03999567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen and Paper Digit Symbol Substitution Test (DSST)
Description: The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
Study: NCT04024878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Needle Biopsy
Description: Surgical procedure
Study: NCT03999567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)
Description: Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
Study: NCT01958606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Description: Treadmill exercise using bursts of concentrated effort alternated with recovery periods

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Aerobic Training
Description: Moderate intensity continuous aerobic exercise on a treadmill
Study: NCT01848821

Intervention type: DEVICE
Group type: OTHER
Intervention: OASIS Ultra
Description: Porcine derived intestinal submucosa
Study: NCT03645031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Acute Intermittent Hypoxia
Description: Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Acute Intermittent Hypoxia
Description: Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
Study: NCT04380129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy-conversation sessions
Description: The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. The musical hearing will include Helen Bonny's program Caring, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio~* Dvorak - Serenade in E-Dur, Larghetto~* Warlock - Capriol Suite, Pieds en I'air

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Music Listening to Helen Bonny's programme.
Study: NCT00255801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targretin® (bexarotene)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study: NCT02583191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-molecular heparine
Description: LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily
Study: NCT02128516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral powder in sachet
Study: NCT01158508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
Study: NCT01848821

Intervention type: DEVICE
Group type: OTHER
Intervention: Wound VAC Standard Therapy
Description: Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
Study: NCT00992446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study: NCT02128516

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral powder in sachet
Study: NCT00992446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02128516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral powder in sachet
Study: NCT03306706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole pea muffins
Description: 2 muffins containing whole peas

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split pea muffins
Description: 2 muffins containing split peas

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffins
Description: 2 muffins containing wheat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffins
Description: 2 muffins containing wheat
Study: NCT02772484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study: NCT00446589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: iv 1mg ibandronate monthly for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: sc injection using a pen like device during every hemodialysis session (thrice a week)
Study: NCT02262052

Intervention type: OTHER
Group type: OTHER
Intervention: MRDTI
Description: MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
Study: NCT03791827

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
Study: NCT02290951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab multiple dose levels
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab multiple dose levels
Description: Administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab multiple dose levels
Description: Administered by subcutaneous (SC) injection
Study: NCT03791827

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.

Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d

Intervention type: DRUG
Intervention: Azathioprine
Description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d

Intervention type: DRUG
Intervention: Azathioprine
Description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d

Intervention type: DRUG
Intervention: Tacrolimus
Description: The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h

Intervention type: DRUG
Intervention: Cyclosporine A
Description: The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h

Intervention type: DRUG
Intervention: Cyclosporine A
Description: The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h

Intervention type: DRUG
Intervention: Rituximab
Description: The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
Study: NCT01557894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSOFIE
Description: Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
Study: NCT03277521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
Study: NCT00674778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Any percutaneous cardiovascular procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any percutaneous cardiovascular procedure
Study: NCT00929812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon hydrochloride (GlucaGen®)
Description: 1 mg/1 ml of glucagon hydrochloride intramuscularly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 1 ml NaCl 0.9% intramuscularly
Study: NCT02902796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
Study: NCT04509765

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Linac Based VMAT TBI
Description: Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
Study: NCT01788176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one single intravenous infusion of 100ml of saline.
Study: NCT05730634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: Atorvastatin 40mg once daily for three months
Study: NCT02732717

Intervention type: OTHER
Intervention: ultrasound (observation)
Description: Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave).

Intervention type: OTHER
Intervention: ultrasound (observation)
Description: Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave).
Study: NCT03022227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: telemedicine applied to adult cochlear implant users' follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine
Description: telemedicine applied to adult cochlear implant users' follow-up
Study: NCT04585152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.